Precigen (NASDAQ:PGEN) Reaches New 12-Month High – Should You Buy?

Precigen, Inc. (NASDAQ:PGEN)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $6.04 and last traded at $5.9150, with a volume of 1701755 shares trading hands. The stock had previously closed at $5.86.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PGEN. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. HC Wainwright lifted their price objective on Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Citigroup reissued an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Precigen presently has a consensus rating of “Hold” and an average target price of $12.50.

Precigen Stock Performance

The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. The firm has a market capitalization of $2.11 billion, a P/E ratio of -5.02 and a beta of 1.06. The company’s 50 day moving average is $4.33 and its 200-day moving average is $4.18.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $23.25 million during the quarter, compared to the consensus estimate of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. As a group, equities analysts anticipate that Precigen, Inc. will post -0.02 EPS for the current year.

Insider Transactions at Precigen

In other Precigen news, CFO Harry Jr. Thomasian sold 41,884 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $182,614.24. Following the transaction, the chief financial officer owned 554,535 shares in the company, valued at approximately $2,417,772.60. This represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Helen Sabzevari sold 119,250 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $519,930.00. Following the completion of the sale, the chief executive officer directly owned 3,768,872 shares of the company’s stock, valued at $16,432,281.92. This trade represents a 3.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 232,968 shares of company stock valued at $1,015,740 in the last 90 days. Corporate insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Hedge funds have recently bought and sold shares of the business. State of Wyoming bought a new stake in Precigen during the 1st quarter valued at $27,000. NBC Securities Inc. bought a new position in shares of Precigen in the fourth quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Precigen during the third quarter valued at about $39,000. Royal Bank of Canada grew its holdings in shares of Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Precigen during the third quarter worth about $41,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.